(Q57628798)

English

Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial

article by J. E. A. Blair et al published 23 July 2011 in European Heart Journal

In more languages

Statements

scholarly article

0 references

Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial (English)

0 references

0 references

1 reference

based on heuristic

inferred from title

hospitalization

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

M. Metra

4

0 references

Liliana Grinfeld

10

object named as

L. Grinfeld

0 references

14

object named as

F. Zannad

0 references

12

object named as

K. Swedberg

0 references

author name string

J. E. A. Blair

1

0 references

P. S. Pang

2

0 references

R. W. Schrier

3

0 references

B. Traver

5

0 references

T. Cook

6

0 references

U. Campia

7

0 references

A. Ambrosy

8

0 references

J. C. Burnett

9

0 references

A. P. Maggioni

11

0 references

J. E. Udelson

13

0 references

M. A. Konstam

15

0 references

M. Gheorghiade

16

0 references

publication date

23 July 2011

0 references

European Heart Journal

0 references

32

0 references

20

0 references

2563-2572

0 references

High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR238

21 January 2018

Renal impairment and outcomes in heart failure: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR238

21 January 2018

Both in- and out-hospital worsening of renal function predict outcome in patients with heart failure: results from the Coordinating Study Evaluating Outcome of Advising and Counseling in Heart Failure (COACH).

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR238

21 January 2018

Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR238

21 January 2018

The prognostic importance of different definitions of worsening renal function in congestive heart failure

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR238

21 January 2018

Relationship between heart failure treatment and development of worsening renal function among hospitalized patients

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR238

21 January 2018

Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure?

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR238

21 January 2018

Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR238

21 January 2018

Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CH

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR238

21 January 2018

Cardiorenal interactions: insights from the ESCAPE trial

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR238

21 January 2018

Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST).

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR238

21 January 2018

Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR238

21 January 2018

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR238

21 January 2018

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR238

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR238

21 January 2018

Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR238

21 January 2018

Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR238

21 January 2018

Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR238

21 January 2018

Associations between worsening renal function and 30-day outcomes among Medicare beneficiaries hospitalized with heart failure

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR238

21 January 2018

Characteristics of patients with improvement or worsening in renal function during treatment of acute decompensated heart failure.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR238

21 January 2018

Acute kidney injury increases risk of ESRD among elderly

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR238

21 January 2018

Dialysis-requiring acute renal failure increases the risk of progressive chronic kidney disease

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR238

21 January 2018

Neutrophil gelatinase-associated lipocalin in the diagnosis of type 1 cardio-renal syndrome in the general ward.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR238

21 January 2018

Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR238

21 January 2018

Acute heart failure syndromes: current state and framework for future research

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR238

21 January 2018

Phase III clinical trial end points in acute heart failure syndromes: A virtual roundtable with the acute heart failure syndromes international working group

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR238

21 January 2018

Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR238

21 January 2018

Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR238

21 January 2018

Testing for chronic kidney disease: a position statement from the National Kidney Foundation

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR238

21 January 2018

Identifiers

10.1093/EURHEARTJ/EHR238

0 references

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57628798&oldid=1552824953"